Open AccessPhase I Dose‐Escalation Study of Pilaralisib (SAR245408, XL147), a Pan‐Class I PI3K Inhibitor, in Combination With Erlotinib in Patients With Solid Tumors
Author(s) -
Soria JeanCharles,
LoRusso Patricia,
Bahleda Ratislav,
Lager Joanne,
Liu Li,
Jiang Jason,
Martini JeanFrançois,
Macé Sandrine,
Burris Howard
Publication year - 2015
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2014-0449
Subject(s) - medicine , erlotinib , rash , pharmacodynamics , pharmacology , adverse effect , pharmacokinetics , epidermal growth factor receptor , egfr inhibitors , oncology , gastroenterology , cancer
Background. This phase I study evaluated the maximum tolerated dose (MTD), safety, pharmacokinetics (PK), and pharmacodynamics of pilaralisib (SAR245408), an oral pan‐class I phosphoinositide 3‐kinase (PI3K) inhibitor, in combination with erlotinib, an epidermal growth factor receptor (EGFR) inhibitor. Methods. In a 3 + 3 dose‐escalation study, patients with advanced solid tumors received pilaralisib capsules once daily (21 days per 28‐day cycle; 50–600 mg) plus erlotinib tablets once daily (28 days per 28‐day cycle; 100 or 150 mg). An MTD expansion cohort of patients with non‐small cell lung cancer who had previously received treatment with an EGFR inhibitor was included. Results. Thirty‐five patients were enrolled. Only one patient had an EGFR activating mutation. One dose‐limiting toxicity was reported (grade 4 drug reaction or rash with eosinophilia and systemic symptoms). MTD was pilaralisib 400 mg plus erlotinib 150 mg. The most commonly reported treatment‐related adverse events were rash (62.9%), diarrhea (42.9%), and fatigue (40.0%). Pilaralisib PK findings were consistent with previous studies, suggesting erlotinib had no effect on pilaralisib pharmacokinetics. Pharmacodynamic analyses indicated moderate inhibition of PI3K, mitogen‐activated protein kinase, and EGFR pathways. Of 27 evaluable patients, one had a partial response (3.7%) and 14 (51.9%) had stable disease. There was no association between molecular alterations of PI3K pathway components and clinical activity. Conclusion. Pilaralisib plus erlotinib had limited antitumor activity. Safety findings were similar to recent studies of single‐agent pilaralisib or other PI3K inhibitors.